Patents by Inventor Volker Schnecke

Volker Schnecke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agents
    Patent number: 8143263
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 27, 2012
    Assignee: Astrazeneca AB
    Inventors: Stuart Norman Lile Bennett, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • THERAPEUTIC AGENTS 414
    Publication number: 20100093757
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Application
    Filed: August 4, 2009
    Publication date: April 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Stuart Norman Lile BENNETT, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087
    Publication number: 20090306133
    Abstract: The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for their therapeutic use, particularly in the treatments of obesity and diabetes mellitus.
    Type: Application
    Filed: December 19, 2008
    Publication date: December 10, 2009
    Applicant: ASTRAZENECA AB
    Inventors: David Blomberg, Anders Holmen, Petra Johannesson, Pernilla Sorme, Pernilla Stahlberg, Kay Brickmann, Volker Schnecke, Eric Wellner, Ragnar Hovland, Asa Mansson, Alleyn Plowright
  • Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders
    Publication number: 20080269275
    Abstract: Compounds of Formula I wherein R1, D, R2, A and R3 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: May 29, 2006
    Publication date: October 30, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Dean Brown, William Blackwell, Frances M. McLaren, Volker Schnecke, Reed W. Smith, Gary Steelman, Xia Wang, Rebecca Urbanek, Steven Wesolowski